OncoCyte Corporation
OCX
$2.73
$0.083.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.21M | -60.66M | -43.14M | -36.14M | -39.94M |
| Total Depreciation and Amortization | 1.72M | 1.56M | 1.33M | 1.41M | 1.54M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.13M | 39.71M | 22.71M | 17.28M | 20.53M |
| Change in Net Operating Assets | -3.38M | -1.32M | -672.00K | -557.00K | -987.00K |
| Cash from Operations | -22.74M | -20.71M | -19.78M | -18.00M | -18.86M |
| Capital Expenditure | -799.00K | -516.00K | -566.00K | -496.00K | -305.00K |
| Sale of Property, Plant, and Equipment | 4.00K | 4.00K | 0.00 | 231.00K | 354.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 367.00K | 367.00K | 367.00K |
| Cash from Investing | -795.00K | -512.00K | -199.00K | 102.00K | 416.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -299.00K | -201.00K | -149.00K | -93.00K | -89.00K |
| Issuance of Common Stock | 56.96M | 27.81M | 15.83M | 15.81M | 13.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -5.39M | -5.39M | -5.39M | -5.39M | -1.12M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.28M | -1.80M | -725.00K | -538.00K | -427.00K |
| Cash from Financing | 48.99M | 20.43M | 9.56M | 9.79M | 12.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.45M | -796.00K | -10.42M | -8.11M | -6.23M |